JP2010536365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536365A5 JP2010536365A5 JP2010521579A JP2010521579A JP2010536365A5 JP 2010536365 A5 JP2010536365 A5 JP 2010536365A5 JP 2010521579 A JP2010521579 A JP 2010521579A JP 2010521579 A JP2010521579 A JP 2010521579A JP 2010536365 A5 JP2010536365 A5 JP 2010536365A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pkib
- prostate cancer
- double
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101000978006 Homo sapiens cAMP-dependent protein kinase inhibitor beta Proteins 0.000 claims description 78
- 102100023516 cAMP-dependent protein kinase inhibitor beta Human genes 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 51
- 206010060862 Prostate cancer Diseases 0.000 claims description 50
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 50
- 101000635408 Homo sapiens Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 Proteins 0.000 claims description 49
- 102100031009 Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 Human genes 0.000 claims description 49
- 230000014509 gene expression Effects 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 25
- 108091081021 Sense strand Proteins 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 230000000692 anti-sense effect Effects 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 230000004071 biological effect Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 7
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 230000004942 nuclear accumulation Effects 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 101000994505 Drosophila melanogaster cAMP-dependent protein kinase catalytic subunit 1 Proteins 0.000 claims 5
- 239000003550 marker Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 77
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 41
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 32
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 16
- 108020004459 Small interfering RNA Proteins 0.000 description 14
- 239000004055 small Interfering RNA Substances 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 10
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000002991 immunohistochemical analysis Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101150011488 NAALADL2 gene Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 101150026024 pkiB gene Proteins 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000000439 tumor marker Substances 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101000610781 Homo sapiens Proteasome subunit alpha type-2 Proteins 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000004965 Prostatic Intraepithelial Neoplasia Diseases 0.000 description 2
- 206010071019 Prostatic dysplasia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100040364 Proteasome subunit alpha type-2 Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- -1 phenoxyacetyl Chemical group 0.000 description 2
- 210000000064 prostate epithelial cell Anatomy 0.000 description 2
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000009133 Arylsulfatases Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 150000008574 D-amino acids Chemical group 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 101001133631 Lysinibacillus sphaericus Penicillin acylase Proteins 0.000 description 1
- 238000007807 Matrigel invasion assay Methods 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108010073038 Penicillin Amidase Proteins 0.000 description 1
- 101710123388 Penicillin G acylase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 101150032670 est gene Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95785307P | 2007-08-24 | 2007-08-24 | |
| US3603008P | 2008-03-12 | 2008-03-12 | |
| PCT/JP2008/065234 WO2009028521A1 (en) | 2007-08-24 | 2008-08-20 | Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536365A JP2010536365A (ja) | 2010-12-02 |
| JP2010536365A5 true JP2010536365A5 (enExample) | 2011-10-06 |
Family
ID=40387239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521579A Withdrawn JP2010536365A (ja) | 2007-08-24 | 2008-08-20 | 前立腺癌の治療及び診断の標的遺伝子のための、ｐｋｉｂ及びｎａａｌａｄｌ２ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120022128A1 (enExample) |
| EP (1) | EP2195425A4 (enExample) |
| JP (1) | JP2010536365A (enExample) |
| KR (1) | KR20100075452A (enExample) |
| CN (1) | CN101855346A (enExample) |
| BR (1) | BRPI0815757A2 (enExample) |
| CA (1) | CA2697512A1 (enExample) |
| RU (1) | RU2010111116A (enExample) |
| TW (1) | TW200920405A (enExample) |
| WO (1) | WO2009028521A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945848B2 (en) * | 2009-07-31 | 2015-02-03 | Chromocell Corporation | Methods and compositions for identifying and validating modulators of cell fate |
| KR101164645B1 (ko) * | 2011-10-07 | 2012-07-20 | 대한민국 | Ｇｃｐⅱ 돌연변이를 함유하는 알츠하이머 예방 및 치료용 약학적 조성물 |
| GB201303308D0 (en) * | 2013-02-25 | 2013-04-10 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| GB201304612D0 (en) * | 2013-03-14 | 2013-05-01 | Cancer Rec Tech Ltd | Diagnostic and prognostic biomarkers for prostate cancer and other disorders |
| AU2014375206B2 (en) * | 2014-01-03 | 2021-09-30 | Innosign B.V. | Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression. |
| KR101824303B1 (ko) | 2015-08-06 | 2018-01-31 | 부경대학교 산학협력단 | 종이형 전립선암 진단센서, 이의 제조방법, 및 이를 이용한 전립선암 진단방법 |
| CN114177296B (zh) * | 2021-12-16 | 2023-05-26 | 上海交通大学医学院附属第九人民医院 | Mpc的过表达或活性提高在制备预防和/或治疗前列腺癌的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005044976A2 (en) | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005083118A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| EP2343384A3 (en) * | 2004-03-23 | 2012-01-04 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
| WO2006026051A2 (en) * | 2004-08-03 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma |
| EP1907582B1 (en) * | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP2336780A1 (en) * | 2005-07-27 | 2011-06-22 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
-
2008
- 2008-08-20 KR KR1020107006479A patent/KR20100075452A/ko not_active Withdrawn
- 2008-08-20 TW TW097131697A patent/TW200920405A/zh unknown
- 2008-08-20 RU RU2010111116/10A patent/RU2010111116A/ru not_active Application Discontinuation
- 2008-08-20 JP JP2010521579A patent/JP2010536365A/ja not_active Withdrawn
- 2008-08-20 CA CA2697512A patent/CA2697512A1/en not_active Abandoned
- 2008-08-20 EP EP08828317A patent/EP2195425A4/en not_active Withdrawn
- 2008-08-20 BR BRPI0815757-0A2A patent/BRPI0815757A2/pt not_active IP Right Cessation
- 2008-08-20 WO PCT/JP2008/065234 patent/WO2009028521A1/en not_active Ceased
- 2008-08-20 US US12/674,664 patent/US20120022128A1/en not_active Abandoned
- 2008-08-20 CN CN200880109851A patent/CN101855346A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression | |
| JP4375932B2 (ja) | 悪性新生物の診断および処置 | |
| US20240277803A1 (en) | Nme inhibitors and methods of using nme inhibitors | |
| MXPA01005169A (es) | Promocion o inhibicion deangiogenesis y cardiovascularizacion. | |
| CN102099491A (zh) | 调节血管生成的新靶标 | |
| JP2017520574A (ja) | メタドヘリン−ｓｎｄ１相互作用を遮断するペプチドの癌の治療としての使用 | |
| JP2022519120A (ja) | 抗ｎｍｅ抗体および癌または癌転移の治療方法 | |
| Rocha et al. | The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer | |
| JP5139332B2 (ja) | 成長刺激タンパク質の使用 | |
| JP2008507251A (ja) | 新規筋成長調節因子 | |
| JP2023123748A (ja) | 転移性癌の診断及び治療の方法 | |
| Udayakumar et al. | Fibroblast growth factor‐1 transcriptionally induces membrane type‐1 matrix metalloproteinase expression in prostate carcinoma cell line | |
| JP7033143B2 (ja) | Ｄｃｔｎ１タンパク質とｒｅｔタンパク質との融合タンパク質 | |
| US10563265B2 (en) | Use of RHOA in cancer diagnosis and inhibitor screening | |
| JP5843170B2 (ja) | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 | |
| KR20230048234A (ko) | Dna 손상 복구 효율 조절용 조성물 | |
| EP1699460B1 (en) | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune | |
| WO2022244807A1 (ja) | Ｌｔｋ融合遺伝子 | |
| Lin et al. | Alpha2 macroglobulin, a PSA binding protein, is expressed in human prostate stroma | |
| CN101405392A (zh) | 一种新型的doublecortin样激酶基因mRNA剪接异构体及其在神经外胚层起源癌症的诊断和治疗中的应用 | |
| CN101522918A (zh) | 用于治疗和诊断癌症及癌转移的组合物及方法 | |
| KR101083562B1 (ko) | Ｆｌｊ２５４１６ 유전자의 신규한 용도 | |
| JP2007530921A (ja) | 非小細胞肺癌に対する腫瘍マーカーおよび治療標的としてのａｄａｍ８ | |
| US10865415B2 (en) | Prevention, diagnosis and treatment of cancer overexpressing GPR160 | |
| JPWO2005021739A1 (ja) | Ｎｏｘ１ポリペプチドに対する抗体、Ｎｏｘ１遺伝子を利用したガン診断方法、及びガン増殖抑制物質のスクリーニング方法 |